KR940011014A - 안정화된 수퍼옥사이드 디스뮤타아제(sod) 조성물 - Google Patents

안정화된 수퍼옥사이드 디스뮤타아제(sod) 조성물 Download PDF

Info

Publication number
KR940011014A
KR940011014A KR1019930025154A KR930025154A KR940011014A KR 940011014 A KR940011014 A KR 940011014A KR 1019930025154 A KR1019930025154 A KR 1019930025154A KR 930025154 A KR930025154 A KR 930025154A KR 940011014 A KR940011014 A KR 940011014A
Authority
KR
South Korea
Prior art keywords
superoxide dismutase
cyclodextrin
hydroxypropyl
mannitol
solution
Prior art date
Application number
KR1019930025154A
Other languages
English (en)
Inventor
메이어 라이너
Original Assignee
디이터 라우디엔, 루돌프 호프만
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디이터 라우디엔, 루돌프 호프만, 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 디이터 라우디엔, 루돌프 호프만
Publication of KR940011014A publication Critical patent/KR940011014A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

본 발명은 첨가제로서 사이클로덱스트린, 바람직하게는 하이드록시프로필-β-사이클덱스트린, 및 당 또는 당 알콜중 어느 하나, 바람직하게는 만니톨을 함유하는 안정화된 수퍼옥사이드 디스뮤타아재(SOD) 조성물에 관한 것이다.
본 발명에 따른 조성물의 동결건조된 제제는 재용해시 고 효소활성을 갖는 등명한 용액을 형성한다.

Description

안정화된 수퍼옥사이드 디스뮤타아제(SOD) 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (22)

  1. 수퍼옥사이드 디스뮤타아제, 사이클로텍스트린, 및 당류 및 당 알콜류를 포함하는 그룹중에서 선택된 물질을 함유함을 특징으로 하는 가용성 조성물.
  2. 제1항에 있어서, 수퍼옥사이드 디스뮤타아제가 망간 수퍼옥사이드 디스뮤타아제임을 특징으로 하는 조성물.
  3. 제1항에 있어서, 사이클로덱스트린이 하이드록시프로필-β-사이클로덱스트린임을 특징으로 하는 조성물.
  4. 제1항에 있어서, 당 알콜이 만니톨 임을 특징으로 하는 조성물.
  5. 수퍼옥사이드 디스뮤타아제, 사이클로덱스트린, 및 알콜류 및 당 알콜류를 포함하는 그룹중에서 선택된 물질을 사용함을 특징으로 하는 가용성조성물의 제조방법.
  6. 제5항에 있어서, 당 알콜이 만니톨임을 특징으로 하는 방법.
  7. 제5항에 있어서, 수퍼옥사이드 디스뮤타아제, 사이클로덱스트린, 및 당류 또는 당 알콜류를 포함하는 그룹중에서 선택된 물질을 함유하는 용액을 동결건조시킴을 특징으로 하는 방법.
  8. 제7항에 있어서, 용액중의 수퍼옥사이드 디스뮤타아제의 함량이 0.1 내지 60mg/㎖일을 특징으로 하는 방법.
  9. 제7항 또는 8항에 있어서, 수퍼옥사이드 디스뮤타아제가 망간 수퍼옥사이드 디스뮤타아제임을 특징으로 하는 방법.
  10. 제7항에 있어서, 사이클로덱스트린이 하이드록시프로필-β-사이클로덱스트린임을 특징으로 하는 방법.
  11. 제10항에 있어서, 용액중의 하이드록시프로필-β-사이클로텍스트린의 함량이 0.5 내지 20% (중량/부피)임을 특징으로 하는 방법.
  12. 제10항에 있어서, 용액중의 하이드록시프로필-β-사이클로덱스트린의 함량이 1 내지 11%(중량/부피)임을 특징으로 하는 방법.
  13. 제10항에 있어서, 용액중의 하이드록시프로필-β-사이클로덱스트린의 함량이 1 내지 6% (중량/부피)임을 특징으로 하는 방법.
  14. 제7항에 있어서, 당 알콜이 만니톨임을 특징으로 하는 방법.
  15. 제14항에 있어서, 용액중의 만니톨 함량이 0.5 내지 10%(중량/부피)임을 특징으로 하는 방법.
  16. 제14항에 있어서, 용액중의 만니톨 함량이 1 내지 5%(중량/부피)임을 특징으로 하는 방법.
  17. 수퍼옥사이드 디스뮤타아제, 사이클로덱스트린, 및 당류 및 당알콜류를 포함하는 그룹중에서 선택된 물질을 함유함을 특징으로 하는 약제학적 조성물.
  18. 제17항에 있어서, 수퍼옥사이드 디스뮤타아제가 망간 수퍼옥사이드 디스뮤타아제임을 특징으로 하는 약제학적 조성물.
  19. 제17항에 있어서, 사이클로덱스트린이 하이드록시프로필-β-사이클로덱스트린임을 특징으로 하는 약제학적 조성물.
  20. 제17항에 있어서, 당 알콜이 만니톨임을 특징으로 하는 약제학적 조성물.
  21. 포유류 및 사람의 질환을 치료하거나 예방하는 의약을 제조하기 위한 제1항 내지 4항에 따른 조성물의 용도.
  22. 포유류 및 사람의 질환을 치료하거나 예방하는 의약을 제조하기 위한 수퍼옥사이드 디스뮤타아제, 하이드록시프로필-β-사이클로덱스트린 및 만니톨의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930025154A 1992-11-27 1993-11-24 안정화된 수퍼옥사이드 디스뮤타아제(sod) 조성물 KR940011014A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4239877.0 1992-11-27
DE4239877A DE4239877C1 (de) 1992-11-27 1992-11-27 Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung

Publications (1)

Publication Number Publication Date
KR940011014A true KR940011014A (ko) 1994-06-20

Family

ID=6473780

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930025154A KR940011014A (ko) 1992-11-27 1993-11-24 안정화된 수퍼옥사이드 디스뮤타아제(sod) 조성물

Country Status (16)

Country Link
US (1) US5464614A (ko)
EP (1) EP0599262A3 (ko)
JP (1) JPH06199691A (ko)
KR (1) KR940011014A (ko)
AU (1) AU671495B2 (ko)
CA (1) CA2110087A1 (ko)
DE (1) DE4239877C1 (ko)
FI (1) FI935264A (ko)
HU (1) HUT65580A (ko)
IL (1) IL107754A (ko)
MX (1) MX9307433A (ko)
NO (1) NO934289L (ko)
NZ (1) NZ250285A (ko)
PH (1) PH30788A (ko)
TW (1) TW252046B (ko)
ZA (1) ZA938848B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101010055B1 (ko) * 2008-06-16 2011-01-21 한국전력공사 디스크 유량계 및 그의 제어방법

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
US6132712A (en) * 1996-12-11 2000-10-17 A. Glenn Braswell Superoxide dismutase stabilized with fragments of casein and pharmaceutical compositions incorporating same
US20040132653A1 (en) * 1997-01-30 2004-07-08 Biopharm Gmbh Lyophilized composition of bone morphogenetic factor human MP52
CA2278546C (en) * 1997-01-30 2008-04-01 Hoechst Marion Roussel Ltd. Freeze-dried composition of bone morphogenetic protein human mp52
WO2003000853A2 (en) * 2001-06-20 2003-01-03 Caprion Pharmaceuticals Inc. Protein aggregation assays and uses thereof
DE10223783A1 (de) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers
US8318803B2 (en) * 2003-10-31 2012-11-27 Tae-Yoon Kim EC SOD and use thereof
JP4891083B2 (ja) 2003-10-31 2012-03-07 テー−ヨーン キム Ｅｃｓｏｄ及び細胞侵透性ｅｃｓｏｄとこれらの用途
EP2483407A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2014064637A1 (en) * 2012-10-26 2014-05-01 Lupin Limited Stable pharmaceutical composition of tnfr:fc fusion protein
EP3091069A1 (en) * 2015-05-06 2016-11-09 Fitoplancton Marino S.L. Method for obtaining a biomass of a microalga of the species tetraselmis chuii enriched in superoxide dismutase (sod)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5712993A (en) * 1980-06-23 1982-01-22 Fujirebio Inc Isolation of superoxide dismutase
IT1142524B (it) * 1981-05-27 1986-10-08 Serono Ist Farm Composizione farmaceutica contenente orgoteina
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
US4447355A (en) * 1982-04-07 1984-05-08 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
EP0123291A2 (en) * 1983-04-20 1984-10-31 Kyowa Hakko Kogyo Co., Ltd. Method for stabilizing interferon
EP0138111B1 (en) * 1983-10-03 1991-11-21 Chiron Corporation Superoxide dismutase cloning and expression in microorganisms
JPS60155133A (ja) * 1983-11-09 1985-08-15 シンビオテイツクス　コ−ポレイシヨン アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン
JPS60228422A (ja) * 1984-04-26 1985-11-13 Suntory Ltd 安定化された生理活性物質製剤
CA1340597C (en) * 1984-08-27 1999-06-22 Haim Aviv Expression vectors containing pl promoter, and engineered restriction site for convenient replacement of ribosomal binding site, plasmids containing the vectors, hosts containing the plasmids and related methods
JPS61111690A (ja) * 1984-11-06 1986-05-29 Ube Ind Ltd 組換えｄｎａおよびその用途
CA1232850A (en) * 1985-01-17 1988-02-16 Albert D. Friesen Purification of superoxide dismutase
ES8800982A1 (es) * 1985-07-05 1987-12-01 Takeda Chemical Industries Ltd Un metodo para producir la enzima superoxido-dismutasa modificada con derivados de polietilenglicol y triazina.
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
JPS6279778A (ja) * 1985-10-04 1987-04-13 Suntory Ltd 新規ス−パ−オキシドデイスムタ−ゼ及びその製造方法
IE59498B1 (en) * 1985-11-22 1994-03-09 Bio Technology General Corp Human manganese superoxide dismutase analog, plasmid for its expression and method of recovering it in enzymatically active form
US5246847A (en) * 1985-11-22 1993-09-21 Bio-Technology General Corp. Polypeptide analogs of human manganese superoxide dismutase and compositions and complexes thereof
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
US5260204A (en) * 1987-03-14 1993-11-09 Boehringer Ingelheim International Gmbh Human manganese superoxide dismutase (hMn-SOD)
EP0691401A1 (en) * 1987-03-27 1996-01-10 Bio-Technology General Corporation Human manganese superoxide dismutase analogs, pharmaceutical compositions containing them, and use thereof
DE3851257T4 (de) * 1987-05-21 1996-07-11 Suntory Ltd Azyliertes Derivat von Superoxid-Dismutase und dieses enthaltende Zusammensetzung.
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
JPH01304882A (ja) * 1988-06-03 1989-12-08 Ube Ind Ltd ヒトＣｕ，Ｚｎ型スーパーオキシドジスムターゼの安定保存法
EP0416037B1 (en) * 1988-06-14 1995-07-26 Chiron Corporation Superoxide dismutase analogs having novel binding properties
JPH0610138B2 (ja) * 1988-07-12 1994-02-09 日本化薬株式会社 スーパーオキシドディスムターゼ組成物
US5538878A (en) * 1988-08-08 1996-07-23 Calgene, Inc. Superoxide dismutase expression in plants
EP0359617A3 (en) * 1988-09-02 1990-04-04 Plant Genetic Systems, N.V. Stress-tolerant plants
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
IL96136A (en) * 1989-11-07 2000-12-06 Bio Technology General Corp Use of hydrophobic chromatography in a method for purification of copper-zinc superoxide dismutase from cells containing same
JPH0568541A (ja) * 1990-12-28 1993-03-23 Asahi Chem Ind Co Ltd 活性なエクストラセルラー・スーパーオキシドジスムターゼの製造方法
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101010055B1 (ko) * 2008-06-16 2011-01-21 한국전력공사 디스크 유량계 및 그의 제어방법

Also Published As

Publication number Publication date
AU671495B2 (en) 1996-08-29
CA2110087A1 (en) 1994-05-28
FI935264A (fi) 1994-05-28
JPH06199691A (ja) 1994-07-19
HU9303365D0 (en) 1994-03-28
ZA938848B (en) 1995-04-06
NO934289L (no) 1994-05-30
EP0599262A3 (de) 1994-11-23
NZ250285A (en) 1995-04-27
HUT65580A (en) 1994-07-28
IL107754A0 (en) 1994-02-27
AU5195393A (en) 1994-06-09
US5464614A (en) 1995-11-07
FI935264A0 (fi) 1993-11-26
IL107754A (en) 1996-10-16
PH30788A (en) 1997-10-17
DE4239877C1 (de) 1994-03-17
MX9307433A (es) 1994-08-31
TW252046B (ko) 1995-07-21
EP0599262A2 (de) 1994-06-01
NO934289D0 (no) 1993-11-26

Similar Documents

Publication Publication Date Title
KR940011014A (ko) 안정화된 수퍼옥사이드 디스뮤타아제(sod) 조성물
EP0366154B1 (en) Use of a composition as a cosmetic product
EP0872248A2 (en) Pharmaceutical vehicles for reducing transdermal flux
ATE253941T1 (de) Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden
GB2080682A (en) Antiherpetically active lipstick
KR970703132A (ko) 듀오카르마이신 유도체의 안정화 방법(method for stabilizing duocarmycin derivatives)
JPH02215707A (ja) 皮膚化粧料
KR880009639A (ko) 서방성 매트릭스 제형
JPH09506906A (ja) 純粋な形態又は植物抽出物としてのマンジフェリン又はその誘導体を活性成分として含有する化粧用又は医薬用組成物
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
HK1046220A1 (en) Stable, spray-dried composition in a carbohydrate substrate and process for obtaining said composition.
CA2294457A1 (en) Pharmaceutical composition for application to mucosa
KR910011244A (ko) 로젠지제
GB2063668A (en) Beta-cyclodextrin for use in the treatment of acne
IE781032L (en) Pharmaceutical compositions
RU2136270C1 (ru) Твердая фармацевтическая форма
EP0657176A2 (en) Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
AU4419497A (en) Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
KR900013964A (ko) 활성형 비타민 d₃류 제제용 조성물 및 이를 함유하는 안정한 활성형 비타민 d₃류 제제의 제조방법
RU2216549C2 (ru) Пиперазин-циклодекстриновый комплекс и лекарственное средство, содержащее указанный комплекс
US5407667A (en) Composition containing inclusion complex of glutathione and a or β-cyclodextrine
IE801402L (en) Gastric acid neutralizing agents
EP0867181A1 (en) Nasal melatonin composition
JPH08157356A (ja) 口腔用錠剤
JPH07157431A (ja) 安定なプロスタグランジンｅ製剤

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid